Wensing Annemarie M, Calvez Vincent, Ceccherini-Silberstein Francesca, Charpentier Charlotte, Günthard Huldrych F, Jacobsen Donna M, Paredes Roger, Shafer Robert W, Richman Douglas D
University Medical Center Utrecht, The Netherlands and Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris.
Top Antivir Med. 2025 May 21;33(2):457-473.
Certain mutations in HIV-1 that emerge during exposure to antiretroviral drugs may have varied impact on the effectiveness of current and subsequent treatments for HIV. This 2025 edition of the International Antiviral Society-USA (IAS-USA) drug resistance mutations list updates the Figure last published in November 2022 based on new data that have become available. The mutations listed are those that have been identified by specific criteria to contribute to a reduced virologic response to currently available antiretroviral drugs. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs, and therefore, to consider when making clinical decisions regarding the components of an initial antiretroviral regimen and changing a regimen in the settings of avoiding toxicity, regimen simplification, or previous or current virologic failure.
在接触抗逆转录病毒药物期间出现的某些HIV-1突变，可能会对当前及后续的HIV治疗效果产生不同影响。美国国际抗病毒学会（IAS-USA）2025年版的耐药性突变列表，根据已获得的新数据，更新了上一次于2022年11月发布的图表。列出的突变是那些已通过特定标准确定会导致对现有抗逆转录病毒药物的病毒学反应降低的突变。该图表旨在帮助从业者识别与抗逆转录病毒药物耐药性相关的关键突变，从而在就初始抗逆转录病毒治疗方案的组成部分做出临床决策，以及在避免毒性、简化治疗方案或既往或当前病毒学失败的情况下更改治疗方案时予以考虑。
